The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease.
about
Hyperresponsiveness to inhaled but not intravenous methacholine during acute respiratory syncytial virus infection in miceBiomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severityAsthma phenotypes: the intriguing selective intervention with MontelukastEpstein-Barr virus primes human polymorphonuclear leucocytes for the biosynthesis of leukotriene B4How exposures to biologics influence the induction and incidence of asthmaNebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlersCell-specific expression of RANTES, MCP-1, and MIP-1alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus.Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology.Novel pathways in the pathogenesis of respiratory syncytial virus disease.Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus.Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing.The Kaposi's sarcoma-associated herpesvirus (KSHV)-induced 5-lipoxygenase-leukotriene B4 cascade plays key roles in KSHV latency, monocyte recruitment, and lipogenesis.Bronchiolitis, respiratory syncytial virus, and recurrent wheezing: what is the relationship?Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virusLeukotriene receptor antagonists--risks and benefits for use in paediatric asthma.Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection.Antibody enhancement of respiratory syncytial virus stimulation of leukotriene production by a macrophagelike cell line.Development of local immunity: role in mechanisms of protection against or pathogenesis of respiratory syncytial viral infections.Acute and long-term effects of viral bronchiolitis in infancy.Economic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection.Respiratory syncytial virus prevention and therapy: past, present, and future.Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses.Immunopathogenesis associated with formaldehyde-inactivated RSV vaccine in preclinical and clinical studies.Respiratory syncytial virus induces leukotriene C4 synthase expression in bronchial epithelial cells.The Human Immune Response to Respiratory Syncytial Virus Infection.Role of early-life environmental influences in the development of asthma. How painful is it when you catch a bad cold too early?Intrapulmonary administration of leukotriene B4 enhances pulmonary host defense against pneumococcal pneumonia.Why do viruses make infants wheeze?Respiratory syncytial virus immunology.Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus.Montelukast for respiratory syncytial virus bronchiolitis: significant effect or provocative findings?Urine leukotriene E and eosinophil cationic protein in nasopharyngeal aspiration from young wheezy children.Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.Leukotriene receptor antagonists in virus-induced wheezing : evidence to date.Role of interferon gamma in the pathogenesis of primary respiratory syncytial virus infection in BALB/c mice.Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease.Virus-induced airway hyperresponsiveness and asthma.Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus.Incidence of acute otitis media associated with group A and B respiratory syncytial virus infections.
P2860
Q25256827-B89164EE-B659-4A96-A54E-EAAB01BA8A73Q27010165-68F7FDC1-973B-49DF-AA5C-706B70BAA5EDQ28071735-4545D9F2-F22D-4CC2-BB0A-4CE3E3F5DE3FQ28365981-0AD1B19F-05C0-4447-A236-302EB372A578Q30446644-71D3735E-0B4E-4644-88B3-78B42DCD2CEDQ33624122-45F367C1-EB2C-4F53-9C4B-9516E7AD188EQ33784028-1F02CAA3-7E7D-4217-BE17-3205A3E8C67EQ33835641-1EB0AA5D-6CAE-41AC-A7FB-09F1F0F0EDE2Q33988549-E479755F-0C00-4FC4-9ABC-1E2F8AAAD405Q34118491-7261EE9F-F76C-455B-B493-29B5AC99422EQ35015651-F3AC7677-950B-435A-B717-AFCD6AA670E2Q35066362-7671F4F5-EB14-49EA-B434-9756B2A59D4EQ35130249-A3BD9626-EED3-45E6-BEAD-883D53F92B77Q35625743-8DD86B7B-2F12-4612-83C7-9F6148985E76Q35779312-AACD3CEB-BA0A-468B-A363-99F6A80F0697Q35994233-370CF598-B0CA-4F87-8AA8-6B87074E6536Q36322131-8ED2E385-27C9-428C-BAB7-6072F7B75500Q36797899-F587C46C-F362-4B0A-BD06-7A502955FD09Q37822410-CE1A9DC0-4DD1-4504-B8F6-27B268D7416FQ37822415-59A912B8-19E0-490C-8E4B-B9F4C11F05B0Q37822416-C826CAE4-1C4C-446E-B0F2-1D8E56B7BFEBQ37857806-1899E08A-27AA-4BD0-9B42-68B625027FD6Q37880221-D662ABB3-2001-48E1-857D-8B7DBDA8DB09Q39007664-B63A1474-D982-440D-8891-1883EC76CBF1Q39063567-15F0A00C-7CFE-4F00-8B38-41F6A1F080AEQ39127064-A1133CBC-034E-4446-9D9B-0A3C0F1080A5Q40140409-CA36D99C-9256-4DBD-922D-DDF0C6EAF097Q40331243-87020332-AB36-4057-9BA5-C5D0313E2908Q41096329-31FB6E34-C4EB-447A-BD3D-A19A5CC617D8Q41475667-57DDFC96-CD6B-4013-95A6-B2FBE1EF6740Q43954408-204E798B-381F-474B-9308-85C84FCEAB35Q44294567-B8435511-193A-4844-ACE9-A23C73A716B6Q44512641-A36F8CEE-F6D8-40ED-A2C6-F7A44790D49EQ45150106-C94C71F6-657E-4037-8F08-3961E5AF60E0Q45409401-13943AAC-F29F-4E2E-8731-3A55F1B25C76Q45740485-DD59684E-B260-4A7F-80ED-D517CC1B2567Q45746926-751D08B8-B1CF-4C26-9033-4ABB162ED13CQ45755627-6272855D-182B-450B-B398-53986D810292Q45780217-A36345A9-ED6A-4974-A852-6A1B61AE15F4Q45785019-CCFA4528-954F-4ECB-AA5B-EC47BCF2C059
P2860
The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
The release of leukotrienes in ...... in obstructive airway disease.
@en
The release of leukotrienes in ...... in obstructive airway disease.
@nl
type
label
The release of leukotrienes in ...... in obstructive airway disease.
@en
The release of leukotrienes in ...... in obstructive airway disease.
@nl
prefLabel
The release of leukotrienes in ...... in obstructive airway disease.
@en
The release of leukotrienes in ...... in obstructive airway disease.
@nl
P2093
P1433
P1476
The release of leukotrienes in ...... in obstructive airway disease.
@en
P2093
De Castro G
Krystofik DA
Volovitz B
Welliver RC
P304
P356
10.1203/00006450-198810000-00018
P407
P577
1988-10-01T00:00:00Z
P5875
P6179
1012022767